DDInter1570 DDInter481
Chronic angina is a common cardiovascular condition affecting millions worldwide and causes significant disability while interfering with daily activities. Ranolazine is a well-tolerated piperazine derivative used for the management of this condition, offering relief from uncomfortable and debilitating symptoms. With a mechanism of action different from drugs used to treat the same condition, ranolazine is a promising anti-anginal therapy. It was originally approved by the FDA in 2006.
Darolutamide is a nonsteroidal androgen receptor antagonist for the treatment of castrate-resistant, non-metastatic prostate cancer (nmCRPC). This condition occurs in the majority of patients with advanced prostate cancer who have been treated with androgen receptor antagonists. Though prior treatment for prostate cancer has been successful for these patients, the cancer eventually progresses to become resistant to existing therapies. This warrants further treatment. The goal of treatment with darolutamide is to delay the progression of prostate cancer to metastatic disease, increasing quality of life and life expectancy for those with advanced prostate cancer.[A189054,A189063] Darolutamide was developed by Bayer HealthCare Pharmaceuticals Inc. and approved by the FDA on July 30th, 2019.
Ranolazine {u} (Compound) resembles {v} (Compound) Bupivacaine
Bupivacaine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Aprepitant
Aprepitant {u} may cause a minor interaction that can limit clinical effects when taken with {v} Darolutamide
Ranolazine {u} (Compound) resembles {v} (Compound) Eprazinone
Eprazinone {u} (Compound) resembles {v} (Compound) Modafinil
Modafinil {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Darolutamide
Ranolazine {u} (Compound) resembles {v} (Compound) Bupivacaine
Bupivacaine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lorlatinib
Lorlatinib {u} may lead to a major life threatening interaction when taken with {v} Darolutamide
Ranolazine {u} (Compound) resembles {v} (Compound) Acetophenazine
Acetophenazine {u} (Compound) resembles {v} (Compound) Nefazodone
Nefazodone {u} may cause a minor interaction that can limit clinical effects when taken with {v} Darolutamide
Ranolazine {u} (Compound) resembles {v} (Compound) Carvedilol
Carvedilol {u} (Compound) resembles {v} (Compound) Propafenone
Propafenone {u} may cause a minor interaction that can limit clinical effects when taken with {v} Darolutamide
Ranolazine {u} (Compound) resembles {v} (Compound) Propranolol
Propranolol {u} (Compound) resembles {v} (Compound) Propafenone
Propafenone {u} may cause a minor interaction that can limit clinical effects when taken with {v} Darolutamide
Ranolazine {u} (Compound) binds {v} (Gene) CYP2D6
CYP2D6 {u} (Gene) is bound by {v} (Compound) Nevirapine
Nevirapine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Darolutamide
Ranolazine {u} (Compound) resembles {v} (Compound) Carvedilol
Carvedilol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Fluconazole
Fluconazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Darolutamide
Ranolazine {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Nefazodone
Nefazodone {u} may cause a minor interaction that can limit clinical effects when taken with {v} Darolutamide
Ranolazine {u} (Compound) binds {v} (Gene) SCN9A
SCN9A {u} (Gene) is bound by {v} (Compound) Carbamazepine
Carbamazepine {u} may lead to a major life threatening interaction when taken with {v} Darolutamide
Ranolazine (Compound) resembles Bupivacaine (Compound) and Bupivacaine may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Aprepitant may cause a minor interaction that can limit clinical effects when taken with Darolutamide
Ranolazine (Compound) resembles Eprazinone (Compound) and Eprazinone (Compound) resembles Modafinil (Compound) and Modafinil may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide
Ranolazine (Compound) resembles Bupivacaine (Compound) and Bupivacaine may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib and Lorlatinib may lead to a major life threatening interaction when taken with Darolutamide
Ranolazine (Compound) resembles Acetophenazine (Compound) and Acetophenazine (Compound) resembles Nefazodone (Compound) and Nefazodone may cause a minor interaction that can limit clinical effects when taken with Darolutamide
Ranolazine (Compound) resembles Carvedilol (Compound) and Carvedilol (Compound) resembles Propafenone (Compound) and Propafenone may cause a minor interaction that can limit clinical effects when taken with Darolutamide
Ranolazine (Compound) resembles Propranolol (Compound) and Propranolol (Compound) resembles Propafenone (Compound) and Propafenone may cause a minor interaction that can limit clinical effects when taken with Darolutamide
Ranolazine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Nevirapine (Compound) and Nevirapine may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide
Ranolazine (Compound) resembles Carvedilol (Compound) and Carvedilol may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole and Fluconazole may cause a minor interaction that can limit clinical effects when taken with Darolutamide
Ranolazine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Nefazodone (Compound) and Nefazodone may cause a minor interaction that can limit clinical effects when taken with Darolutamide
Ranolazine (Compound) binds SCN9A (Gene) and SCN9A (Gene) is bound by Carbamazepine (Compound) and Carbamazepine may lead to a major life threatening interaction when taken with Darolutamide